Member Info for handybrownone

No interest was due in 2023 on these loans. So it helps overall but cash flow wise not a great deal. It makes bank borrowing easier I guess

Like the comments. Excellent break down. Clearly a target of 120k scrips in 2023 and only doing 10k in the first Q means a LOT has to be done. 2Q feels tricky as still in transition. It's got to get to at least 25k otherwise its not credible that they will catch up.

Couple of comments 1. the teams are pushing but eventually doctors will prescribe without any pushing (pull). 2. the improvement in net profits per scrip as they get covered. So at some point there is an inflection - hoepfully

It's an easy calc based upon end of year guidance they need CQGR (quarterly) of around 30% to reach 500,000 annual scrip by end of 2025. If they wish to reach the 2024 target then it needs to be closer to 40% for 2023/24. You can calculate the CQGR for 2022 - I estimate it to be Q1 to Q2 was 85% and 2022 Q2 to Q3 was 38% and Q3 to Q4 was 35%. But starting from such low numbers means small differences in numbers change %. So all eyes are on 2023 numbers 1H - if they maintain 30%+ happy days - on track

Is there enough cash to 2024 when revenues start or they need more? I think the market is saying "more"

It was a non cash loss

The operating loss of £0.2m was impacted by non-cash items, including:



£7.2m amortisation of intangible assets arising from acquisitions undertaken during prior years;

£0.7m non-cash depreciation; and

£0.1m share-based payments.

Amati fund say they have exited Renalytix - admit they should have top sliced at the peak but now 100% out.

https://openprescribing.net/chemical/0901011Y0/

Technically it is a recommendation. The Approval is granted later by the EU Commission it is a few days/weeks later. I think that will count for the CVR

I think the presentations from the Docs was a bit dull - but I'm not a medic. The bit I thought was interesting is that they both viewed it as a first line options and just how bad the side effects are on oral iron. The issue is rebates and the econmics - but the thing with health systems if you can show health economic data i.e. skimping on a few quid on oral leaves you with more expensive outcomes later then they will get paid. This takes time. The problem when you are the bottom of a J curve it feels like a straight line for ever. Sometimes the J never kicks in. Patience. I have missed so many opportunities in the last 10 years. Two biggest - Tristel - owned at 20p and liked the company! Sold for 100%. GW Pharma - listed on AIM - dual listed on NASDAQ delisted AIM bought by Jazz for xbn. Liked the company sat on a non-moving sp for 2 years and gave up!

Saw the results yesterday and a good proxy for business. Reporting levels > pre covid. So volume parcels is up. Well worth watching as they post regular updates on volumes. Bodes well for DX. I think where Royal Mail fail is that they are so scruffy. The vans are never repaired and the drivers where whatever they like and often see them smoking etc etc

Wake up - it went ex-dividend today and we just got 19p. So the price is higher than Friday. The bid was at 135p + 19p for the special divi

Ordinary Shares marked ex-Interim Dividend - Tuesday, 1 June.

By all means buy some more

Not sure how you got to 150p - I got 14p. Out by a factor of 10. You divide the $115m by the no of share and convert c to p.

In the USA notice periods are usually very short. This really surprised me when I discussed employment contracts in USA but the normal practice is not to have one! One company I worked for only had contracts for the most senior people that were critcical. Many people are employed "at will" and the terms are those established in law. Honestly you can;t read anything into the shortness of the period. I did think though that as he was Illumina and the license he might have been encouraged?

You are right the existing plant can't move the needle. The plant they are building is tiny. It can't even make enough to supply one powerstation. That is not the point. The point is to hook a big player get them to build a massive plant, license the patent and get a few $ per tonne and repeat ad nauseam until dominant in USA in pellets. Between now (nothing) and infinity (everything) there are execution risks galore along the way. I have a small position and will buy more on each step up the ladder.

Having been in and out more times than a vicar at a tarts party I can say that I think finally I shall stick. The fundamental issues with TRX is that it is very slow and hard to scale up manufacture. It's not a drug where you can push a button and make more. This is really what the issue has always been cash flow and production. If 2021 is cahd flow neutral or positive and all future raises are off the table then it will jump up. My concern is that COVOD continues to disrupt in 2021.

A little more detail on dates and schedule wouldn't go amiss! I note that year end is 31st Dec but last year results were not announced until 1st June.

They are all muppets. They did a rubbish job launching in the UK so why would it be better in USA. It's beyond belief that they have been approved since July 2019 and not found a partner. Such a wet MD

What is the financial benefit to Renal on this? Struggling to find it....

I agree. I've entered and exited ODX over a period of 5 years ! I was initially excited about their automated allergen test as I know the huge barriers to entry in creating a validated library. Insane waste of money to pull the plug but using people to chip away at this one test at a time makes no sense now. Also I was excited by Visitect but we know they had to redevelop it and had stability trial issues! In a sense the difficulty in making it works gives me confidence that they can deliver (eventually!). I rode the bronco all the way up to 60p from some initial purchases at 10-18p. I bought in again before the results and will buy some more today. Hopefully a steadier ride. SP only rose and fell due to retail investor sentiment that is not a reason to buy or sell just something to watch for an entry point on a long term hold.

It's not just a fine. If found guilty they may be prevented from participating in forwarding contract with the USA government and subject to DoJ oversight at the board level. You'd be wise to make your stake back again before the trial ends and then take it off the table and let the free shares run